Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seres Therapeutics

9.31
-0.7700-7.64%
Volume:83.17K
Turnover:809.01K
Market Cap:81.16M
PE:531.91
High:10.20
Open:10.02
Low:9.25
Close:10.08
Loading ...

Seres Therapeutics Shares up 10.2% on 'Breakthrough Therapy' Tag for Blood Infection Treatment

THOMSON REUTERS
·
09 Dec 2024

BUZZ-Seres Therapeutics rises on 'breakthrough therapy' tag for blood infection treatment

Reuters
·
09 Dec 2024

Seres Therapeutics granted Breakthrough Therapy designation for SER-155

TIPRANKS
·
09 Dec 2024

BRIEF-FDA Grants Breakthrough Therapy Designation To Seres Therapeutics’ SER-155

Reuters
·
09 Dec 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)

THOMSON REUTERS
·
09 Dec 2024

Seres Therapeutics Inc - FDA Meeting on Next Study of Ser-155 Expected in Q1 2025

THOMSON REUTERS
·
09 Dec 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

GlobeNewswire
·
09 Dec 2024

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

GlobeNewswire
·
22 Nov 2024

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

Simply Wall St.
·
15 Nov 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...

GuruFocus.com
·
14 Nov 2024

Seres Therapeutics Reports Q3 2024 Results and Strategic Progress

TIPRANKS
·
14 Nov 2024

Seres Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
14 Nov 2024

Seres reports Q3 EPS from continuing operations (33c), consensus (24c)

TIPRANKS
·
14 Nov 2024

Seres Therapeutics (MCRB) Gets a Buy from TD Cowen

TIPRANKS
·
13 Nov 2024

Seres Therapeutics Inc reports results for the quarter - Earnings Summary

Reuters
·
13 Nov 2024

BRIEF-Seres Therapeutics Reports Q3 2024 Financial Results And Provides Business Updates

Reuters
·
13 Nov 2024

Seres Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
13 Nov 2024

Seres Therapeutics Q3 2024 GAAP EPS $(0.33) Misses $(0.25) Estimate, Seres Had $66.8M In Cash And Cash Equivalents, That Is Expected To Fund Operations Into The Fourth Quarter Of 2025

Benzinga
·
13 Nov 2024

Seres Therapeutics Inc: Co Expects to Fund Operations Into Q4 2025

THOMSON REUTERS
·
13 Nov 2024

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

THOMSON REUTERS
·
13 Nov 2024